NCT03693326 is a Phase 2 clinical trial of PDR001 in Cancer, sponsored by Asan Medical Center.

Who is sponsoring NCT03693326?

NCT03693326 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03693326?

Interventions in NCT03693326: PDR001.

What condition does NCT03693326 study?

NCT03693326 studies Cancer, Lung Cancer Metastatic, Immunotherapy.

Is NCT03693326 still recruiting?

NCT03693326 is currently status unknown. Last updated 3 October 2018.

Last reviewed 2018-10-03 · How we verify

NCT03693326

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Status unknown Phase 2 Last updated 3 October 2018

What this trial tests

Phase 2 trial testing PDR001 in Cancer in 70 participants. Status unknown.

Timeline

1 November 2018

Primary endpoint
30 June 2020

30 June 2022

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 November 2018
Primary completion	30 June 2020
Estimated completion	30 June 2022
Sites	1 location across South Korea

Drugs / interventions tested

PDR001 — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →
Lung Cancer Metastatic — all drugs for Lung Cancer Metastatic →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Asan Medical Center

Who can join

18 and older, any sex, with Cancer or Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting <i>KRAS</i> Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.
Uras IZ, Moll HP, Casanova E. · · 2020 · cited 109× · PMID 32560574 · DOI 10.3390/ijms21124325
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.
Xie M, Xu X, Fan Y. · · 2021 · cited 46× · PMID 34012925 · DOI 10.3389/fonc.2021.672612
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E, Epistolio S, Dazio G, Cefalì M, et al · · 2022 · cited 20× · PMID 36077640 · DOI 10.3390/cancers14174103
Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients.
Jacobs F, Cani M, Malapelle U, Novello S, et al · · 2021 · cited 14× · PMID 34944952 · DOI 10.3390/cancers13246332
Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.
Nindra U, Pal A, Lea V, Lim SH, et al · · 2023 · cited 3× · PMID 37796807 · DOI 10.1371/journal.pone.0292087

Verify or expand the search:

Other trials of PDR001

Trials testing the same drug.

NCT07157345 — Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease · Phase 1 · recruiting
NCT04895748 — DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & · Phase 1 · terminated
NCT04544111 — PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · Phase 2 · active not recruiting
NCT04237649 — KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors · EARLY_PHASE1 · terminated
NCT04058756 — Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With · Phase 1 · active not recruiting

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03693326 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 3 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03693326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing